SYNERGY-COPD
Modelling and simulation environment for systems medicinen(Chronic obstructive pulmonary disease -COPD- as a use case)
| Coordinatore | FUNDACIO PRIVADA BARCELONA DIGITAL CENTRE TECNOLOGIC
Organization address
address: C/ Roc Boronat 117 contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Totale costo | 4˙572˙502 € |
| EC contributo | 3˙494˙000 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2009-6 |
| Funding Scheme | CP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-02-01 - 2014-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FUNDACIO PRIVADA BARCELONA DIGITAL CENTRE TECNOLOGIC
Organization address
address: C/ Roc Boronat 117 contact info |
ES (Barcelona) | coordinator | 0.00 |
| 2 |
BIOMAX INFORMATICS AG
Organization address
address: ROBERT KOCH STRASSE 2 contact info |
DE (PLANEGG) | participant | 0.00 |
| 3 |
BUDAPESTI MUSZAKI ES GAZDASAGTUDOMANYI EGYETEM
Organization address
address: MUEGYETEM RAKPART 3 contact info |
HU (BUDAPEST) | participant | 0.00 |
| 4 |
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Organization address
address: Villarroel 170 contact info |
ES (BARCELONA) | participant | 0.00 |
| 5 |
INFERMED LIMITED
Organization address
address: BEDFORD SQUARE 25 contact info |
UK (LONDON) | participant | 0.00 |
| 6 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 7 |
LINKCARE HEALTH SERVICES SL
Organization address
address: CALLE VILLARROEL 170 contact info |
ES (BARCELONA) | participant | 0.00 |
| 8 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 0.00 |
| 9 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: BROWNLOW HILL, FOUNDATION BUILDING 765 contact info |
UK (LIVERPOOL) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Synergy will develop a simulation environment and a decision-support system aiming at enabling deployment of systems medicine. The three core elements are a knowledge base (KB), an inference engine (IE), and a graphical visualisation environment (GVE). The project focuses on patients with chronic obstructive pulmonary disease (COPD).
The KB will include five well established physiological models addressing: 1) Central and peripheral O2 transport and utilization, 2) Pulmonary gas exchange, 3) Regional-lung heterogeneities in ventilation and perfusion, 4) Skeletal muscle bioenergetics, and 5) Mitochondrial reactive oxygen species (ROS) generation. These models will be written in systems biology markup language (SBML) and vertically integrated. Ontologies will be used as the default knowledge-representation system. The KB will include multi-level data from experimental studies (BioBridge), data from a multicentre longitudinal study on COPD phenotyping (PAC-COPD) and public datasets.
The IE will enable to explore associations over the KB, perform transversal multi-scale model integration and related simulations including interactions among O2-availability/O2-utilization, ROS generation, systemic inflammation and abnormal tissue remodelling.
The Web-based GVE will facilitate relevant simulations in a more intuitive way with respect to the state of the art, addressing two main user profiles: bio-researchers and clinicians.The focus will be on underlying mechanisms of COPD phenotypes associated with poor prognosis. Disease model validation and refinement will be done using a well-established, large dataset (ECLIPSE) together with experimental studies designed to test 'in silico' generated hypotheses. Besides the use of the simulation environment by bio-researchers for optimal experimental design, the Synergy platform will be a relevant decision-support tool for integrated healthcare strategies aiming at modulating the evolution of COPDs.